Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

arter ending March 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward- looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.


    Media Contact:            Investor Contact:

    Maria Cantor              Sally Curley

    (617) 768-6690            (617) 768-6140


CONTACT: Media, Maria Cantor, +1-617-768-6690; Investors, Sally Curley,+1-617-768-6140, both of Genzyme Corp.

Web site: http://www.genzyme.com//

Company News On-Call: http://www.prnewswire.com/comp/113803.html /

Ticker Symbol: (NASDAQ-NMS:GENZ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... Aug. 28, 2014 Takeda Pharmaceutical Company ... commitment and submissions of data from a 10-year ... the United States (U.S.) Food and ... and the Japanese Ministry of Health, Labour, and ... Devices Agency (PMDA) for pioglitazone containing medicines, including ...
(Date:8/28/2014)... 28, 2014  In anticipation of the upcoming MEDevice ... available for the first time. Industry Overview: Medtech & ... offers a snapshot of San Diego,s ... from the latest employment statistics to current venture capital investment ... Diego such a vital part of the global ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2
(Date:8/28/2014)... Dallas, TX (PRWEB) August 29, 2014 ... and in-depth study on the current state of the ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... 2014 Arizona State University graduate student ... has been named one of five finalists in Entrepreneur ... This is the fourth consecutive year that an ASU ... Schoepf, co-founder of SafeSIPP, and JJ Tang, co-founder of ... In 2011, ASU dominated the competition: Three of the ...
(Date:8/28/2014)... exit strategy from the war, now may be the time ... to veterans, says a Perspective piece in the New ... doing more of the same is to fail to recognize ... structure pose in the longer run," said William Weeks, from ... David Auerbach, from the RAND Corporation, in the August issue ...
(Date:8/28/2014)... Allegheny Health Network and ... designed to advance sports nutrition education, concussion awareness ... scholastic athletes and their families across western Pennsylvania. ... Initiative will offer a comprehensive and multi-disciplined educational ... dynamics involved in pursuing athletic excellence,” said Come ...
Breaking Medicine News(10 mins):Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:A VA exit strategy 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... March 10 Speaker Nancy Pelosi and Majority Whip James E. Clyburn held a photo opportunity this afternoon with representatives from the National Association of Public ... ... ... ...
... uncovered a mechanism for resistance to paclitaxel in ovarian ... chemotherapy resistance. Mohamed K. Hassan, Ph.D., a ... research as a collaborative study with his colleagues when ... in Egypt. Results of this study were presented at ...
... treating tumors with extreme heat or moderate heat may ... presented at the second AACR Dead Sea International Conference ... the Clinic, held March 7-10, 2010. "Low ... in curing both malignant and benign tumors using minimally ...
... , March 10 Omega Protein Corporation (NYSE: OME ), the nation,s leading producer of Omega-3 fish oil and specialty fish meal ... with net income of $12.6 million ( $0.69 per share) for the year ended December 31, 2008 . , ... ... ...
... 10 International Merchant Advisors, Inc. (PK: IMAI) ... announced today that the company is preparing to ... Organic Science, Inc.  Organic Science, Inc. is intended to become ... and is focused on the implementation of Organic,s  plans for ...
... March 10 As part of its continued focus on developing programs designed to meet employers, needs, Regence has acquired the assets of Kinetix Living Corp., ... ... , ... ...
Cached Medicine News:Health News:Pelosi Remarks at Photo Opportunity with the National Association of Public Hospitals 2Health News:Omega Protein Reports 2009 Results 2Health News:Omega Protein Reports 2009 Results 3Health News:Omega Protein Reports 2009 Results 4Health News:Omega Protein Reports 2009 Results 5Health News:Omega Protein Reports 2009 Results 6Health News:Omega Protein Reports 2009 Results 7Health News:Omega Protein Reports 2009 Results 8Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 2Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 3Health News:Regence Invests in Kinetix Living Corp. 2Health News:Regence Invests in Kinetix Living Corp. 3
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Monocular Acuity, Binocular Astigmatism, Acuity Balance, Supression, Binocular Acuity, Fixation Desparity, Muscle Balance, Stereopsis...
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Acuity Vergence: Letter Acuity, Astigmatic,Clock, and Vergence Tests...
Medicine Products: